Sequential treatment emphasized, with additional therapy needed after discontinuation of initial drug
Among adults not selected for vitamin D deficiency, low bone mass, or osteoporosis, no effect seen on total, nonvertebral, or hip fracture risk
Risk for major osteoporotic fractures up for insulin versus metformin for those with HbA1c <7 percent, BMI <25 kg/m2
No reduction in osteoporotic fracture risk seen among women receiving concomitant clodronate and NSAIDs
Among U.S. adults, prevalence of fragility fractures increased for former and current e-cigarette users compared with never users
Lower baseline BMI and greater increase in BMI appear to be protective against postmenopausal bone loss
Adjusted odds ratio for type 2 diabetes further reduced for those with more than eight years of alendronate use
